Deze IPO is nog niet vertaald in uw taal [en]
METIS TECHBIO-P logo

METIS TECHBIO-P

07666 · HKEX
Vermeld

Materia Medica Tech is a biotechnology company driven by artificial intelligence (AI) and innovative nanomaterial technologies.

Vermeld

IPO-tijdlijn

  1. OpenenMay 05
  2. SluitenMay 08
  3. ToezeggingMay 12
  4. BetalingMay 13
  5. LijstMay 13

Kerngegevens

Uitgifteprijs

HKD 10.50

Min. inschrijfkosten

HKD 5,302.94

Uitgegeven aandelen

201.23M

Lotgrootte

500

Totale verhoging

HKD 2112.9M

Geschatte marktplafond

HKD 12.10B

Overheidstoewijzing

5.0%

Internationale plaatsing

95.0%

Bedrijfsoverzicht

Materia Medica Tech is a biotechnology company driven by artificial intelligence (AI) and innovative nanomaterial technologies. It focuses on leveraging targeted drug delivery and drug discovery technologies to accelerate patients’ access to innovative therapies across key disease areas.

Gebruik van opbrengsten

1、Approximately HK$988.5 million (about 50.0%) will be used to support the core technology research, development and advancement of the Company’s artificial intelligence infrastructure and AI-driven nanomaterial platform;

2、Approximately HK$395.4 million (about 20.0%) will be allocated to the ongoing and planned clinical trials within the Company’s artificial intelligence product pipeline;

3、Approximately HK$197.7 million (about 10.0%) will be utilised to develop the Company’s animal health and anti-aging solutions, and expand AI-empowered solutions into such high-growth sectors;

4、Approximately HK$197.7 million (about 10.0%) will be allocated to support the Company’s growth strategy of building a global AI-driven nanomaterial ecosystem;

5、Approximately HK$197.7 million (about 10.0%) will be used as working capital and for other general corporate purposes.

Sponsor Track record

Track-record gegevens worden vernieuwd.

Bemiddelaars en documenten

Sponsors

  • 富瑞金融集團香港有限公司
  • 德意志證券亞洲有限公司
  • 中信證券(香港)有限公司

Underwriters

  • 富瑞金融集團香港有限公司
  • 德意志銀行香港分行
  • 中信里昂證券有限公司
  • 招銀國際融資有限公司
  • 富途證券國際(香港)有限公司

Prospectus PDF

Prospectus PDF →

Hoeksteenbeleggers

  • BlackRock Funds
  • UBS Asset Management (Singapore) Ltd.
  • 国风投创新投资基金股份有限公司
  • Mirae Asset Securities (HK) Limited
  • HHLR Advisors, Ltd.
  • Huadeng Technology Piovt Ventures Ltd
  • Isometry Global Master Fund, L.P.
  • Deerfield Management Company, L.P.
  • RTW Funds
  • Arc Avenue Asset Management Pte. Ltd.
  • 华夏基金(香港)有限公司
  • 富国基金管理有限公司
  • 工银瑞信基金管理有限公司
  • 广发基金管理有限公司
  • Sage Partners Master Fund
  • Lake Bleu Prime Healthcare Master Fund Limited
  • Lazurite Hime L.P.
  • 工银理财有限责任公司

Total

0

54.8% of placement

BBX neemt niet deel aan het toewijzingsproces voor een IPO die op deze pagina wordt vermeld. Deze pagina is uitsluitend ter informatie en is geen beleggingsadvies.